Stockreport

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Inc.  (CRVO) 
PDF - Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in Octo [Read more]